This guidance is the third in a series of four methodological patient-focused drug development guidances that describe how stakeholders can collect and submit patient experience data and other relevant information from patients and caregivers to be used for product development decision-making.
Similar Posts
FDA Roundup: July 14, 2023
The U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency.www.d-pharmacy.com – 711075 – 07/16/2025
Unapproved New Drugs/MisbrandedIngestible Fluoride Drug Products
FDA recommends that ingestible fluoride drug products – typically available as tablets and drops – should be limited to children aged three years and older who are at high risk for tooth decay.Drug Trials Snapshots: VIZZ
Drug Trials Snapshots: VIZZClinical Outcome Assessment (COA): Frequently Asked Questions
Clinical Outcome Assessments (COA) Frequently Asked QuestionsAdvancing Real-World Evidence Program
Advancing Real-World Evidence Program
